SCHEMBL7258656

SCHEMBL7258656

CCOC(=O)[C@H](Cc1ccc(Nc2nc(-c3ccc(F)cc3)cc3ccccc23)cc1)Nc1c(OC(C)C)c(=O)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
NPSR1 Q6W5P4 3/20 0.37
HPGD P15428 2/20 0.37
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
TP53 P04637 1/20 0.36
MAPT P10636 5/20 0.35
EGFR P00533 1/20 0.35
KDR P35968 1/20 0.35
KDM4E B2RXH2 3/20 0.34
GAA P10253 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPR3 P17342 1/20 0.34
ITGB1 P05556 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7258056 0.88 ITGB1 (0.43) NPR3ITGB1ITGA4TACR3
SCHEMBL7258050 0.88 ITGB1 (0.43) NPR3ITGB1ITGA4TACR3
SCHEMBL7105519 0.84 ELANE (0.42) ELANEMEN1KMT2ANPSR1HPGD
SCHEMBL7105524 0.84 ELANE (0.42) ELANEMEN1KMT2ANPSR1HPGD
SCHEMBL7716169 0.83 ELANE (0.40) ELANEMEN1KMT2ANPSR1HPGD
SCHEMBL7716179 0.83 ELANE (0.40) ELANEMEN1KMT2ANPSR1HPGD
SCHEMBL7714237 0.81 ACP1 (0.36) MEN1KMT2ANPSR1HPGDPOLB
SCHEMBL7714235 0.81 MAPT (0.36) MEN1KMT2ANPSR1HPGDPOLB
SCHEMBL7714244 0.81 ACP1 (0.36) MEN1KMT2ANPSR1HPGDPOLB
SCHEMBL7714207 0.79 ITGB1 (0.42) ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305291-A1 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES Celltech R&D Limited (GB) 2003-05-02 EP disclosed
US-20020177605-A1 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES CELLTECH R&D, LTD. (GB) 2002-11-28 US disclosed
US-6469025-B1 FOR THE PROPHYLAXIS OR TREATMENT OF A DISEASE OR DISORDER IN A MAMMAL IN WHICH THE EXTRAVASATION OF LEUKOCYTES PLAYS A ROLE; INHIBITING THE BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS CELLTECH R&D LTD. (GB) 2002-10-22 US disclosed
WO-2002010136-A1 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES CELLTECH R & D LIMITED (GB) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177605-A1 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES ICAM1, VCAM1, CCR1 ELANE 3866/4885MEN1 4668/4885KMT2A 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.